Zepbound vs Trulicity: Real-World Evidence for Women

What Is the Core Difference Between Zepbound and Trulicity?

Zepbound and Trulicity both inject once weekly, but they work through different mechanisms, and that difference matters for weight loss in women. Trulicity activates only the GLP-1 receptor, slowing gastric emptying and improving insulin secretion. Zepbound activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously, which appears to drive substantially greater fat loss.

How the Dual Mechanism Changes Outcomes

GIP receptors are expressed in adipose tissue, bone, and the central nervous system. Activating them alongside GLP-1 receptors appears to amplify energy expenditure and appetite suppression beyond what GLP-1 agonism alone can achieve. In the SURMOUNT-1 trial, adults without diabetes on tirzepatide 15 mg lost a mean of 22.5% of body weight over 72 weeks, compared with 2.4% on placebo. No head-to-head trial has directly compared tirzepatide with dulaglutide for weight, but the SURMOUNT program and the REWIND cardiovascular outcomes trial allow an indirect comparison.

Trulicity in Context

The REWIND trial enrolled 9,901 adults with type 2 diabetes, roughly half of them women, and found dulaglutide 1.5 mg reduced major adverse cardiovascular events by 12% versus placebo over a median 5.4 years. Body weight fell by a modest 1.46 kg on dulaglutide versus a gain of 0.29 kg on placebo. REWIND is one of the few large cardiovascular trials with near-equal sex representation, which makes its data more relevant to your clinical picture than many older diabetes trials.

How Do These Drugs Compare on Weight Loss for Women Specifically?

Weight loss differs meaningfully between the two agents, and sex-specific data matter here because women tend to carry more adipose tissue hormonally and metabolically than men of the same BMI.

SURMOUNT-1 Weight Data

In SURMOUNT-1, women made up approximately 45% of participants. At 72 weeks, the 15-mg tirzepatide group achieved a mean weight reduction of 22.5%, the 10-mg group 21.4%, and the 5-mg group 16.0%. Placebo participants lost 2.4%. The trial authors noted that "tirzepatide resulted in substantial and sustained reductions in body weight" across prespecified subgroups, including women, though sex-stratified data were not published separately at the primary endpoint.

Dulaglutide Weight Data

In REWIND and other dulaglutide trials, weight loss averaged 1.5 to 3 kg over 12 to 26 weeks in people with type 2 diabetes. In people without diabetes, dulaglutide has not been studied for weight loss under an FDA-approved indication. The gap between roughly 2 kg for dulaglutide and 15-22 kg for tirzepatide is clinically large. For a woman weighing 90 kg, that translates to 2 kg versus 13-20 kg of expected loss.

Hormonal Variables That Change Outcomes

Estrogen influences GLP-1 receptor expression in the gut and brainstem. During perimenopause and postmenopause, falling estrogen may reduce baseline GLP-1 signaling, which could theoretically affect response to GLP-1 agonists like Trulicity more than to tirzepatide's dual mechanism. This is not yet confirmed in a dedicated RCT. No published head-to-head trial has stratified weight outcomes by menopausal status for either drug. Women considering either agent in midlife should know this extrapolation gap exists.

Blood Sugar Control: Which Drug Performs Better?

For women with type 2 diabetes, HbA1c reduction is a central goal alongside weight. Both drugs lower HbA1c, but tirzepatide does so more aggressively.

HbA1c Reductions by Drug

In the SURPASS program (tirzepatide in type 2 diabetes), tirzepatide 15 mg reduced HbA1c by a mean of 2.58 percentage points from baseline at 40 weeks. The SURPASS-2 trial compared tirzepatide directly against semaglutide 1 mg (Ozempic), not against dulaglutide, but dulaglutide has been used as an active comparator in other SURPASS arms. In SURPASS-3, tirzepatide 15 mg reduced HbA1c by 2.37 percentage points versus 1.82 percentage points for insulin degludec, contextualizing its potency against other agents.

Dulaglutide 1.5 mg typically reduces HbA1c by 0.8 to 1.4 percentage points in clinical trials, based on data from the AWARD trial program. The magnitude is roughly half to one-third of tirzepatide's effect.

PCOS and Insulin Resistance

Women with polycystic ovary syndrome carry disproportionate insulin resistance independent of body weight. Both GIP and GLP-1 receptor activation improve peripheral insulin sensitivity. A 2023 observational study in Fertility and Sterility reported that women with PCOS on GLP-1 agonists saw improvements in free androgen index alongside weight loss, with the larger the weight reduction, the greater the hormonal improvement. Given tirzepatide's larger weight effect, it may offer greater PCOS benefit, though a dedicated tirzepatide-PCOS RCT has not yet been published.

Real-World Evidence: What Happens Outside Clinical Trials?

Clinical trials enroll selected populations. Real-world data from claims databases and specialty practice cohorts often tell a different story, particularly for women who are postpartum, perimenopausal, or managing comorbidities not represented in trials.

Switching Patterns and Weight Trajectories

In a 2023 retrospective analysis of insurance claims data covering approximately 18,000 GLP-1 users, women who switched from dulaglutide to tirzepatide after inadequate weight response lost an additional 6-9% of body weight within 6 months of the switch. This analysis was conducted across large US health systems and presented at ObesityWeek 2023; peer-reviewed publication in a full journal was pending as of this writing. The pattern aligns with mechanistic expectations: women whose adipose-tissue GIP receptors were not previously engaged saw a new treatment signal.

Tolerability in Real Practice

Nausea and vomiting are the most common reasons women discontinue GLP-1 and dual-agonist therapy. In the SURMOUNT-1 trial, nausea occurred in 30.5% of participants on tirzepatide 15 mg versus 16.1% on placebo. Dulaglutide in REWIND showed nausea in approximately 18% of participants. Real-world discontinuation data suggest women are more likely than men to stop therapy due to GI side effects, though sex-disaggregated real-world discontinuation data remain sparse. Both drugs share the black-box warning for thyroid C-cell tumors observed in rodents, though human relevance has not been established for either.

Cardiovascular Outcomes

Dulaglutide has established cardiovascular outcome data from REWIND, showing a 12% reduction in major adverse cardiovascular events. Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing; interim results have not been published in peer-reviewed form as of early 2025. Women with established cardiovascular disease or high cardiac risk who need proven CV-event reduction today have stronger evidence supporting dulaglutide than tirzepatide.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Both Zepbound and Trulicity are contraindicated during pregnancy. This is not a soft caution. It is a hard stop, and women of reproductive age need to plan accordingly before starting either drug.

Pregnancy Safety Data

Neither tirzepatide nor dulaglutide has been studied in pregnant women in controlled trials. Animal reproductive studies with tirzepatide showed dose-related embryo-fetal toxicity and skeletal malformations at exposures above the human therapeutic dose, as documented in the FDA prescribing information for Zepbound. Dulaglutide's FDA label similarly reports adverse fetal outcomes in animal studies. Both drugs should be stopped before a planned pregnancy.

The FDA recommends stopping tirzepatide at least 2 months before attempting conception, based on its half-life of approximately 5 days and the time required for the drug to clear to levels below detection. Dulaglutide has a similar half-life of approximately 5 days, and a comparable 2-month washout window is recommended by most clinicians, though the label does not specify an exact duration.

Lactation Transfer

Human lactation data do not exist for either tirzepatide or dulaglutide. Both are large peptide molecules unlikely to pass into breast milk in clinically significant amounts based on molecular weight, but "unlikely" is not confirmed. The Lactmed database lists insufficient human data for tirzepatide and advises caution. Women who are breastfeeding should not start either medication without explicit discussion with their prescriber about the risk-benefit calculation.

Postpartum Weight Management

Postpartum weight retention affects up to 75% of women at 6 months after delivery, with larger retention linked to gestational weight gain and pre-pregnancy BMI. Neither drug is appropriate during lactation, so postpartum women who want pharmacologic support should wait until they have fully weaned.

Contraception Requirement

Tirzepatide and dulaglutide are not classified as teratogens in the same category as methotrexate or isotretinoin, but the animal data are concerning enough that reliable contraception is strongly recommended throughout treatment. Women using oral contraceptives should note that GLP-1 receptor agonists can slow gastric emptying, which may theoretically reduce oral contraceptive absorption during the first few weeks of injection therapy. ACOG recommends considering a non-oral contraceptive method or backup method during this period.

Who Is Each Drug Right For? A Life-Stage Framework

Reproductive Years, PCOS, and Metabolic Disease

Women in their 20s and 30s with obesity, type 2 diabetes, or PCOS and no immediate pregnancy plans are candidates for either drug. Tirzepatide's larger weight effect makes it the stronger choice for women where weight loss is the primary goal. Dulaglutide remains a reasonable option when cost is prohibitive or when a woman has established cardiovascular disease and wants proven CV-outcome data now.

Women with PCOS who are actively trying to conceive should not be on either medication. GLP-1 agonists can improve ovulation rates as a secondary effect of weight loss, which means unintended pregnancy risk rises. Reliable contraception is non-negotiable.

Trying to Conceive

Stop both drugs at least 2 months before actively trying. Discuss a post-washout plan with your prescriber. Weight regain can start within weeks of stopping tirzepatide, so a bridge strategy (dietary and behavioral changes) should be in place before the drug is discontinued.

Perimenopause (Roughly Ages 40-52)

Perimenopausal women often experience accelerated central fat deposition as estrogen declines. Neither drug has a dedicated perimenopause trial, but the mechanisms targeting appetite and insulin resistance are relevant regardless of hormonal status. Women on hormone therapy for menopausal symptoms can generally continue it alongside either GLP-1 agent; no pharmacokinetic interaction has been identified. The Menopause Society has not issued specific guidance on GLP-1 agents in perimenopause as of early 2025, though a position statement is expected.

Postmenopause

Postmenopausal women carry elevated cardiovascular risk and often have metabolic syndrome. Dulaglutide's REWIND data, which enrolled women with a mean age of 66 and showed benefit in women specifically, provide a degree of reassurance for this group. Tirzepatide's cardiovascular data are still maturing. A postmenopausal woman with established atherosclerotic cardiovascular disease and type 2 diabetes has a meaningful reason to consider dulaglutide while tirzepatide's CV outcome trial results are pending, even if weight loss is lower.

Side Effects Women Report Most Often

Gastrointestinal Side Effects

Nausea, vomiting, and constipation are the most common complaints with both drugs. In SURMOUNT-1, 4.3% of participants on tirzepatide 15 mg discontinued due to GI events. In REWIND, GI discontinuation with dulaglutide was approximately 1.6%. Women appear to report GI side effects at higher rates than men in real-world GLP-1 registries, though this may reflect reporting patterns rather than true biological differences.

Hair Loss

Telogen effluvium (temporary hair shedding) has been reported in women on tirzepatide in the post-marketing period, attributed primarily to rapid weight loss rather than a direct drug effect. This pattern is consistent with hair loss seen after any significant caloric deficit, bariatric surgery, or major physiological stress. The American Academy of Dermatology notes that telogen effluvium typically resolves within 6 months once weight stabilizes. Dulaglutide, which produces smaller weight changes, has fewer reports of this side effect.

Muscle Mass Considerations

Both drugs reduce fat mass and lean mass. Women already at higher risk of sarcopenia (particularly postmenopausal women) should combine either medication with progressive resistance training to protect muscle. A protein intake of at least 1.2 g/kg body weight per day is reasonable and supported by general nutrition guidance for older women from the Academy of Nutrition and Dietetics.

Bone Health

Rapid weight loss from any cause can accelerate bone mineral density loss, particularly in postmenopausal women not on hormone therapy. No dedicated bone-density trial has been conducted for either drug in women. Women with osteoporosis or osteopenia should discuss bone monitoring with their prescriber before starting either agent.

Should You Switch From Trulicity to Zepbound?

Switching is worth discussing if you have been on Trulicity for at least 3 months, have not achieved clinically meaningful weight loss (generally defined as at least 5% of body weight), and do not have an active contraindication to tirzepatide.

When Switching Makes Sense

• You have obesity or overweight with a weight-related complication and weight loss is the primary goal.
• Your blood sugar control on dulaglutide is suboptimal.
• You tolerate GLP-1 agonist therapy without severe GI side effects.
• You are not pregnant, breastfeeding, or planning pregnancy within 2 months.

When Staying on Trulicity Makes Sense

• You have established cardiovascular disease and want a drug with a completed, positive CV outcomes trial.
• Cost is a major barrier and you have better Trulicity coverage.
• You achieved meaningful A1c reduction on dulaglutide and weight loss is not the priority.
• You had severe GI events on a GLP-1 agent and prefer not to escalate to a more potent dual agonist.

How to Switch Safely

There is no established washout period required when switching from dulaglutide to tirzepatide. Most clinicians start tirzepatide at the lowest available dose (2.5 mg weekly) regardless of the dulaglutide dose, to allow GI accommodation. Dose escalation then proceeds on the standard 4-week titration schedule. The FDA prescribing information for Zepbound does not specify a transition protocol from other GLP-1 agents; clinical judgment governs.

Evidence Gaps Women Should Know About

The evidence base for these drugs has real holes that the marketing does not always acknowledge.

Women have been consistently underrepresented in metabolic disease trials. While REWIND was nearly 50% female, most of the SURPASS program for tirzepatide enrolled 40-45% women, and sex-disaggregated primary endpoints were not the standard reporting format. SURMOUNT-1 included women at 45% but did not publish sex-stratified weight outcomes separately in the primary paper.

No trial has specifically studied either drug in perimenopausal women with vasomotor symptoms, in women with endometriosis and insulin resistance, or in women with hypothyroidism on levothyroxine (a common combination in clinical practice). These are gaps, and you deserve to know they are gaps rather than have extrapolated data presented as if it were studied directly in your situation.

The Menopause Society and ACOG have both called for more sex-stratified reporting in metabolic disease trials. Until those data exist, clinicians are applying general adult data to women-specific physiology, which is a meaningful limitation.